



Portable AI Fluorescence Probe for Monitoring Lesion

Development of a portable AI uorescence diagnostic device for observing tumors and lymph nodes

COMPANY OVERVIEW

Kwang Gi Kim, CEO



Kwang Gi Kim
KMAIN CEO

- **CEO. K-MAIN Co., Ltd**
- Current Professor, Department of Biomedical Engineering. Gachon University
- Currently Director of Medical Device R&D Center. Gachon University Gil Medical Center
- Director of National Cancer Center (NCC)
- 2023 Minister of Health and Welfare Excellence Award
- 2023 President of the Medical Science Academy
- 2021 Medical Informatics Society Academic Award
- SCIE Journals in Medical Devices and AI : 400 Journals
- **SCIE Paper last three years** : 150 Journals
- **Patents** : 50 cases
- **Technology transfer** : 30 cases

Greetings!

K-MAIN corporation was founded in 2023 with the passion and responsibility of the employees.

The company strives to create a healthier world by consistently providing high-quality and innovative solutions with responsibility and trust for customers, partners, employees, and society. Together, we will move forward and grow, contributing to a well-crafted future for everyone.

Company Logo



K-MAIN corp tries to connect and integrate various experts, technologies, and ideas based on AI technology in the medical field. Also, it is a corporation that plays role as a pivot where interactions between medical service providers, researchers and patients are stimulated.



Certifications & History

2023

- **01. K-MAIN corp founded**
- **04. Certificated Venture Company**
Company-Affiliated Research Institute founded
- **05. Seleted as a Supported Company for the Early Start-up Package**
(Ministry of SMEs and StartUps)
- **06. Technology Evaluation by the Incheon Technology Innovation Center**
Selected for BioCore Business Start-up Team (Biocore Business team)
- **07. Selected as move in company at Gachon University Start-up Incubation Center**
Selected for the Hyehwa ALL-SET Customized Defile Technical Collaboration Project (Daejeon University LINK Bussiness group)
Selcted for Market Expansion-Type (Post Paid) Project under the Small and Medium Business Innovation Development Program
- **08. Specialized Researching Business Registration**
Selected as an Institution for the development of an automated care plan model for AI-based cardiovascular disease management
- **09. Selected as Start-up improvement technology development project Stepping Stone Service R&D task**

2024

- **01. Selected for the Early Startup Package**
(Korea Institute of Startup & Entrepreneurship Development)
- **02. Adoption of AI-based digital pathology solution for MMRd classification in endometrial cancer**
- **03. Adoption of AI-based body composition analysis and sarcopenia diagnosis support solution**
- **04. Selected for the High-Growth Startup Commercialization Support Program**
(Seongnam Industry Promotion Agency)
Selected for the AI-Integrated Product Development Program
(Seongnam Industry Promotion Agency)
Selected for the AI Voucher Program
(AI-based digital pathology solution for MMRd classification in endometrial cancer)
- **05. Adoption of AI-based solution for breast lesion detection and diagnostic support**
- **07. Selected for the Deep-Tech TIPS Program** (Ministry of SMEs and Startups)
- **08. Selected for the Startup Growth Technology Development Program** (Ministry of SMEs and Startups)
- **10. Selected for the Eum-Growth Support Program** (Gunpo Industry Promotion Agency)
Adoption of AI-based precision spinal analysis and diagnostic support solution
- **11. Selected for the AI Voucher Program**
(AI-based solution for breast lesion detection and diagnostic support)


2025

- **04. Selected for the AI Commercialization Support Program** (Incheon Technopark)
Selected for the Biohealth R&D Project
(Development of on-device AI-based digital healthcare products using unstructured medical data and synthetic data) (Ministry of Trade, Industry and Energy)
- **06. Selected for the Medical Device Development Support Program**
(Gyeonggi Institute of Science and Technology Promotion)
Selected for the NGS-Based Precision Medicine R&D Project
(Development of a clinical decision support system (CDSS) for gastrointestinal and genitourinary cancer using NGS-clinical data and AI models) (Ministry of Health and Welfare)
- **07. Selected for the KTL Software-Based Medical Device Quality Management System Program**
Selected for the Hyperscale AI Ecosystem Expansion Project
(Stroke imaging synthetic data) (NIA – National Information Society Agency)


MAIN TECHNOLOGY




Dual Sources
(780mm, 405mm)
Various Diseases




Ultra-Compact Size and Weight
Rapid Elagnostics without Site Restrictions




Wireless Operation
Eliminated Blind Spots



AI lesion Detection
Improve accuracy



ADVANCED TECHNOLOGY




Various Indication

Indication

- Gastrointestinal
- Cardiovascular
- Cancer
- Plastic/Reconstructive Sugeries


Can use various Fluorescent contrast agent at once

- Indocyanine green
- Fluorescein sodium
- 5-aminolevulinic acid




End-User

- Hospital & Clinics
- Research Labs
- Pharmaceutical Companies





IMPROVEMENT OF DETECTION ABILITY USING AI AUTOMATED LESION DETECTION SYSTEM



Minimized Size & Weight / Reduced Cost / Lower power consume & Eco-Friendly

COMPUTER ASSISTANCE DETECTION PROGRAM



MAJOR COOPERATIVE NETWORK

